Clinical characteristics of the cohort at baseline
| Number of patients (eyes affected) | 22 (37) |
| Mean age, in years (range) | 36.6 (11–64) |
| Median age, in years (IQR) | 34 (27–43) |
| Male sex, n (%) | 12 (55) |
| Mean follow-up, in months (range) | 20.1 (2–57) |
| Median follow-up, in months (IQR) | 13 (8–30) |
| Mean duration of uveitis prior to adalimumab, in months (range) | 83.2 (12–266) |
| Median duration of uveitis prior to adalimumab, in months (IQR) | 61 (27–114) |
| Bilateral disease at baseline, n (%) | 15 (68) |
| Anatomic diagnosis, n (%) | |
| Anterior uveitis | 10 (45) |
| Intermediate uveitis | 0 (0) |
| Posterior or panuveitis | 12 (55) |
| Retinal vasculitis | 7 (32) |
| Aetiological diagnosis, n (%) | |
| Behçet’s | 8 (36) |
| Juvenile idiopathic arthritis | 3 (14) |
| Ankylosing spondylitis | 4 (18) |
| Psoriasis | 1 (5) |
| Sarcoidosis | 1 (5) |
| Undifferentiated | 5 (23) |
| Eyes with active inflammation at baseline, n (%) | |
| Yes | 19 (51) |
| No | 18 (49) |